{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-058529","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.515436+00:00","generated_at":"2026-06-15T06:22:56.184401+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Hepion Pharmaceuticals effects 1-for-20 reverse stock split to regain Nasdaq compliance","bullets":["Reverse split ratio 1-for-20 effective 4:01pm ET May 10, 2023; split-adjusted trading begins May 11 under same symbol HEPA.","Post-split shares outstanding ~3.81M; CUSIP changed to 426897302.","Primary purpose is to meet Nasdaq minimum bid price requirement for continued listing.","Proportionate adjustments to equity awards and warrants; fractional shares rounded up to next whole share.","CEO states split comes ahead of expected Phase 2 ALTITUDE-NASH biomarker results for rencofilstat."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-058529","json":"https://secwatch.observer/filing/0001104659-23-058529.json","markdown":"https://secwatch.observer/filing/0001104659-23-058529.md","text":"https://secwatch.observer/filing/0001104659-23-058529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923058529/0001104659-23-058529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923058529/tm2315272d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:22:56.184401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d6b151820756812cd92bc47c99ec85aee30ea54","claim":"Hepion Pharmaceuticals, Inc.: Company filed a Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock, effective 4:01 p.m. ET on May 10, 2023, as previously approved by stockholders and board (effective 2023-05-10).","evidence_excerpt":"On May 10, 2023, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923058529/0001104659-23-058529-index.htm","confidence":0.99,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-05-10"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}